8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Boston Scientific reports flat Q3 growth and cuts 2026 sales outlook
Filed with the SEC on · Summarized by InvestorsBot
Boston Scientific reported third-quarter 2026 net sales of $5.138 billion for the period ended September 30, up 1.5% from a year earlier, while GAAP EPS fell to $0.40 from $0.51 and adjusted EPS declined to $0.73 from $0.75. The company now expects full-year 2026 reported sales growth of about 4.25% and adjusted EPS of $3.16-$3.18, while forecasting fourth-quarter sales to decline 1%-3%; it also cited an August 2026 cybersecurity incident and announced product clearances, a Heartflow collaboration, and a new WATCHMAN clinical trial.